|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:age
|
adults
children (some approvals)
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2020
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:boosters
|
yes
bivalent (for Omicron and original strain)
|
|
gptkbp:brand
|
gptkb:Comirnaty
gptkb:Spikevax
|
|
gptkbp:contains
|
gptkb:polyethylene_glycol_(PEG)
messenger RNA
sucrose
salts
lipid nanoparticles
|
|
gptkbp:contraindication
|
severe allergic reaction to ingredients
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Brazil
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:Japan
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
many others
|
|
gptkbp:developedBy
|
gptkb:Moderna
gptkb:Pfizer-BioNTech
|
|
gptkbp:distribution
|
global
|
|
gptkbp:effect
|
high against severe COVID-19
|
|
gptkbp:effectivenessAgainstVariants
|
reduced for some variants
|
|
gptkbp:encodes
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:form
|
two doses
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SARS-CoV-2 mRNA vaccine
|
|
gptkbp:inducedBy
|
immune response
|
|
gptkbp:lactationUse
|
recommended
|
|
gptkbp:pregnancyCategory
|
recommended
|
|
gptkbp:requires
|
gptkb:cold_storage
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
allergic reaction
|
|
gptkbp:storage
|
-20°C (Moderna)
-70°C (Pfizer-BioNTech)
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
nucleoside-modified mRNA
|
|
gptkbp:updatedForVariants
|
yes
|
|
gptkbp:usedFor
|
COVID-19 prevention
|
|
gptkbp:WHOStatus
|
emergency use listing
|
|
gptkbp:bfsParent
|
gptkb:Kizzmekia_Corbett
|
|
gptkbp:bfsLayer
|
6
|